Is NTLA a good stock to buy? We came across a bullish thesis on Intellia Therapeutics, Inc. on Markman Capital Insight’s Substack. In this article, we will summarize the bulls’ thesis on NTLA. Intellia Therapeutics, Inc.'s share was trading at $16.61 as of June 29th.
[caption id="attachment_564482" align="aligncenter" width="750"]Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. NTLA is emerging as a leading player...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.